PeptiGrowth Inc. Is Launching A Novel Synthetic Peptide TGFβ1 Inhibitor, Following Its First Product HGF Alternative Peptide
TOKYO--(BUSINESS WIRE)-- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel peptide called TGFβ1 inhibitor (TGFβ1 binding peptide) which binds to TGFβ1 to inhibit its activity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006425/en/
(Graphic: Business Wire)
Development of Synthetic Peptide Growth Factors by PeptiGrowth
Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.
About TGFβ1 inhibitor (TGFβ1 binding peptide) (Product code: PG-002)
- Inhibitory activity against TGFβ1 (ligand)
Existing small molecule inhibitors must enter the cell to inhibit TGFβ1 activity. On the other hand, PG-002 is a peptide that binds to and exhibits inhibitory activity against TGFβ1 (ligand), which acts outside cells. The inhibitory activity against TGFβ1 was measured by SBE Reporter Assay, and PG-002 showed 100% inhibitory activity at 10nM against 0.13nM TGFβ1 (Figure A). Using the panel assay, we also confirmed that it does not inhibit other signaling pathways. We recommend using PG-002 when the neutralization of TGFβ1 is required in cell culture.
- Product Overview
TGFβ1 inhibitor (TGFβ1 binding peptide)
-20 °C or less
≥95% by HPLC
10 μg, 100 μg (volume per a glass vial)
*This product is for testing and research use only (RUO).
*There is a possibility that the specification would be changed.
About HGF Alternative Peptide (c-Met Agonist) (Product code: PG-001)
Prior to TGFβ1 inhibitor, PeptiGrowth has launched a synthetic peptide growth factor, PG-001, which has the same functions as native Hepatocyte Growth Factor (HGF). PeptiGrowth demonstrated that PG-001 activates c-Met (HGF-target receptor) by phosphorylation and supports cell (HUVEC) proliferation as shown in Figure B and C above respectively.
To Purchase PeptiGrowth Products
To purchase PeptiGrowth products mentioned in this article, please contact the agent in North America, Mitsubishi International Food Ingredients, Inc.
PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the missions to address various challenges that regenerative medicine and cell therapy industry is facing and to contribute to its growth. Since its foundation, PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as the conventional growth factors and cytokines by joint development with PeptiDream.
Following HGF Alternative Peptide and TGFβ1 inhibitor, PeptiGrowth is planning to launch the next product by the end of March, 2022. Details will be updated on its website upon release.
Mitsubishi International Food Ingredients, Inc.
Tel : + 1 (201) 681-1268
Source: PeptiGrowth Inc.
Smart Multimedia GalleryPhoto
(Graphic: Business Wire)